SpringWorks Acquired by Merck KGaA, Darmstadt, Germany for $3.9 Billion

Merck KGaA, Darmstadt, Germany, a global science and technology company, has announced its agreement to acquire SpringWorks Therapeutics, a U.S. biopharmaceutical firm, for $47 per share, amounting to an equity value of approximately $3.9 billion and an enterprise value of $3.4 billion. This acquisition aims to bolster Merck's healthcare segment, particularly by enhancing its position in the treatment of rare tumors and expanding its presence in the U.S. pharmaceutical market. The move is part of Merck's broader strategic plan to strengthen its portfolio through high-quality compound in-licensing and strategic acquisitions. SpringWorks, known for therapies treating severe rare diseases and cancers, will benefit from Merck’s global reach and resources, furthering their impact on patient care. The acquisition, which requires customary regulatory clearances, is expected to close in the latter half of 2025.